| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c3c5dd1d8582b366503230ab4d8a29d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e1797856cf11fd436e9fd09d136c3a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7298a4410ff43c24f173d364d2d7f65e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75b19b9c7666a9a411829069a95d28f2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-11 |
| filingDate |
2008-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f213bb30a8967c3091b818f2e4c9fff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2afbfe9ebeac02ba1b32390b71344aa4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d71557524ac1e7071a832539e08ebb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e513b7a89f8c09b080727aa7f3681fd |
| publicationDate |
2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011098362-A9 |
| titleOfInvention |
Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization |
| abstract |
Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8039025-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012050735-A1 |
| priorityDate |
2005-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |